Extensive thrombus prior to elective percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 13, Issue 7, 2001, Pages 538-541

  Kandzari, David E ^a   Behar, Victor S ^a   Sketch Jr , Michael H ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; EPTIFIBATIDE; HEPARIN; PEPTIDE; TICLOPIDINE;

ARTICLE; CASE REPORT; CORONARY ARTERY THROMBOSIS; ELECTIVE SURGERY; FEMALE; HUMAN; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY THROMBOSIS; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; SURGICAL PROCEDURES, ELECTIVE; TICLOPIDINE;

EID: 0035409353     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin Tirofiban status. Circulation 1999;100:1509-1514.
2. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation: Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000;21:1406-1432.
3. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-1497.
4. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT). N Engl J Med 1998;339;436-443.
5. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000;101:751-757.
6. Block PB, Peterson EC, Krone R, et al. Identification of variables needed to risk adjust outcomes of coronary interventions: Evidence-based guidelines for efficient data collection. J Am Coll Cardiol 1998;32:275-282.
7. Ellis SG, Guetta R, Miller D, et al. Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification scheme. Circulation 1999;100:1971-1976.
8. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-874.
9. Li Y, Spencer FA, Ball S, Becker RC. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists; Potential contributing mechanism of benefit in acute coronary syndromes. J Thromb Thrombolysis 2000;10:69-76.
10. Furman MI, Kreuger LA, Frelinger AL III, et al. GP IIb/IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemostasis 2000;84:492-498.
11. Steinhubl SR, Kereiakes DJ. Ultegra rapid platelet function analyzer, in platelets. In: Michelson AD (ed). Platelets. New York: Academic Press, in press.
12. Mascelli MA, Pezzullo JC, Abernethy DR, et al. Pharmacodynamic profile of acute readministration of abciximab in normal subjects. Am Heart J (in press).
13. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. J Am Coll Cardiol 1999;33:634.
14. Lincoff AM, Califf RM, Molitemo DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet GP IIb/IIIa receptors: Evaluation of platelet IIb/IIIa inhibition in stenting investigators. N Engl J Med 1999;341:319-327.
15. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta 3 blockade with percutaneous coronary intervention: EPIC Investigator Group: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-484.
16. Topol EJ, Lincoff AM, Kereiakes DJ, et al., for the EPIC, EPILOG and EPISTENT Investigators. Multi-year follow-up of abciximab therapy in three randomized, controlled trials of percutaneous coronary revascularization. Circulation (submitted).